PRMT5 Inhibitor Compounds for MTAP-Null Tumor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PRMT5 inhibitors face challenges with selectivity, potency, metabolic stability, and undesirable effects on normal tissues, particularly in tumors with MTAP loss, necessitating the development of targeted inhibitors that minimize adverse effects.
Innovation Solution
Development of compounds that act as PRMT5 inhibitors, specifically designed to target MTAP-null cancer cells by exploiting the accumulation of MTA, which competes with SAM for the PRMT5 catalytic site, thereby selectively inhibiting PRMT5 activity in these cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first generation PRMT5 inhibitors are used to treat tumors, then PRMT5 activity is inhibited in tumors, but adverse effects occur due to inhibition of PRMT5 in normal tissues
Solution Approach 1:
The patent applies local quality by designing PRMT5 inhibitors with specific chemical structures (Formula I compounds) that preferentially accumulate in or bind to PRMT5 in tumor cells with MTAP loss, while having reduced activity in normal tissues. This is achieved through structure-activity relationship optimization where specific substituents (R1, R2, R3a, R3b groups) are selected to enhance tumor selectivity and reduce off-target effects on normal hematopoietic tissues.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical and physical properties of PRMT5 inhibitors to achieve selective tumor targeting. This includes optimizing molecular weight, lipophilicity, and binding affinity parameters of the compounds to enhance their selective accumulation in MTAP-deficient tumor cells while minimizing exposure to normal tissues, thereby improving the therapeutic window.
2Reliability
If PRMT5 inhibitors are designed to be potent against all PRMT5, then broad inhibition is achieved, but selectivity for MTAP-null tumors is reduced
Solution Approach 1:
The patent uses MTA (methylthioadenosine) as an intermediary mechanism. In MTAP-null tumors, MTA accumulates and competes with SAM for binding to PRMT5. The designed inhibitors exploit this by having structures that resemble MTA or by binding to the MTA-PRMT5 complex, thereby achieving selective potent inhibition in MTAP-null tumors while sparing normal cells that do not have MTA accumulation. This intermediary mechanism allows the inhibitors to achieve both potency and selectivity simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit PRMT5 in MTAP-deleted cancer cells, reducing the risk of adverse effects on normal tissues and enhancing therapeutic efficacy.
Implementation Method 1
MTA accumulating in MTAP-deleted cancer cells competes with SAM for binding to the catalytic site of PRMT5 and partially suppresses its enzymatic activity
Data Source
AI summary
The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.